Current Hematologic Malignancy Reports
Overview
Current Hematologic Malignancy Reports is a scientific journal, published by Current Science since 2006 in English. The journal's country of origin is United States and its primary focus areas are oncology and hematology.
Details
Details
Abbr.
Curr Hematol Malig Rep
Publisher
Current Science
Start
2006
End
Continuing
Frequency
Quarterly
p-ISSN
1558-8211
e-ISSN
1558-822X
Country
United States
Language
English
Specialties
Oncology
Hematology
Hematology
Metrics
Metrics
h-index / Ranks: 8115
44
SJR / Ranks: 3818
998
CiteScore / Ranks: 3060
6.80
JIF / Ranks: 3624
2.9
Recent Articles
11.
Farmer I, Radia D
Curr Hematol Malig Rep
. 2024 Aug;
19(5):197-207.
PMID: 39187708
Purpose Of Review: Since identification of Systemic mastocytosis (SM) as a distinct disease entity by the World Health Organisation (WHO), there has been a wealth of new research in therapeutic...
12.
Mora B, Bucelli C, Cattaneo D, Bellani V, Versino F, Barbullushi K, et al.
Curr Hematol Malig Rep
. 2024 Aug;
19(5):223-235.
PMID: 39179882
Purpose Of Review: Myelofibrosis (MF) includes prefibrotic primary MF (pre-PMF), overt-PMF and secondary MF (SMF). Median overall survival (OS) of pre-PMF, overt-PMF and SMF patients is around 14 years, seven...
13.
Pan D, Richter J
Curr Hematol Malig Rep
. 2024 Aug;
19(6):237-245.
PMID: 39145912
Purpose Of Review: The introduction of bispecific antibodies is one of the most significant recent advances in the treatment of relapsed/refractory multiple myeloma. This review will summarize the management of...
14.
Lubke J, Metzgeroth G, Reiter A, Schwaab J
Curr Hematol Malig Rep
. 2024 Jul;
19(5):208-222.
PMID: 39037514
Purpose Of Review: In this review, we aim to explore the optimal approach to patients presenting with eosinophilia, considering recent advances in diagnostic and therapeutic strategies. Specifically, we focus on...
15.
Chohan K, Kapoor P
Curr Hematol Malig Rep
. 2024 Jul;
19(4):163-174.
PMID: 38970645
Purpose Of Review: Waldenström macroglobulinemia is a rare non-Hodgkin lymphoma (NHL) characterized by lymphoplasmacytic bone marrow infiltration associated with an immunoglobulin M (IgM) monoclonal gammopathy. Over the past two decades,...
16.
Tran V, Salafian K, Michaels K, Jones C, Reed D, Keng M, et al.
Curr Hematol Malig Rep
. 2024 Jun;
19(4):186-196.
PMID: 38888822
Purpose Of Review: Measurable residual disease (MRD) is integral in the management of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). This review discusses the current methods used to evaluate MRD...
17.
Pourhassan H, Murphy L, Aldoss I
Curr Hematol Malig Rep
. 2024 Jun;
19(4):175-185.
PMID: 38867099
Purpose Of Review: Glucocorticoids are a mainstay in acute lymphoblastic leukemia treatment and lack of early response is predictive for overall disease prognosis. Given the vital position of glucocorticoids and...
18.
Werk R, Heneghan M, Badawy S
Curr Hematol Malig Rep
. 2024 May;
19(4):153-162.
PMID: 38806875
Purpose Of Review: As society continues to advance in technology, it is important to address how this advancement can impact and enhance patient care. The purpose of this review is...
19.
Kewan T, Stahl M, Bewersdorf J, Zeidan A
Curr Hematol Malig Rep
. 2024 May;
19(3):151.
PMID: 38761360
No abstract available.
20.
Kewan T, Stahl M, Bewersdorf J, Zeidan A
Curr Hematol Malig Rep
. 2024 Apr;
19(3):138-150.
PMID: 38632155
Purpose Of Review: Myelodysplastic syndromes/neoplasms (MDS) represent a diverse group of pathologically distinct diseases with varying prognoses and risks of leukemia progression. This review aims to discuss current treatment options...